Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
E.RaftK
it is not approved by the FDA or EMA for any therapeutic use
World J Gastroenterol 14(2):193 Alkhouri N, Carter-Kent C, Feldstein AE (2011) Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 265,23 per year only 22,10 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Patients seeking treatment for weight loss should consult a physician trained in management of overweight or obesity.
Last updated June 3, 2026 Editorial policy A Weight-Loss Drug With an Unexpected Benefit If youve been anywhere near the news in the past two years, youve heard of GLP-1 receptor agonists drugs like Ozempic, Wegovy, and Mounjaro that have transformed weight loss and diabetes management
US$ 25.71
US$ 22.41
US$ 23.25
US$ 23.46
